AtriCure (ATRC) Q2 2024 earnings summary

Executive summary

• Achieved Q2 2024 revenue of $116.3 million, up 15.2% year-over-year, with strong growth in pain management, open ablation, and appendage management franchises.

• Generated $8.1 million in positive cash flow and $7.8 million in adjusted EBITDA for the quarter.

• Launched new products including cryoSPHERE+ and received FDA clearance for AtriClip FLEX-Mini, with further launches and regulatory approvals in China and Europe.

• Continued investment in clinical trials, notably the LeAAPS stroke reduction trial, and expanded physician training initiatives.

• Focused on innovation and expanding global market opportunities in Afib and pain management.

Financial highlights

• Q2 2024 worldwide revenue: $116.3 million, up 15.2% year-over-year; U.S. revenue: $95.5 million, up 12.5%; international revenue: $20.7 million, up 29.4%.

• Gross margin was 74.7%, down from 76.4% in Q2 2023, due to less favorable mix and higher product costs.

• Adjusted EBITDA was $7.8 million, slightly down from $8.0 million in Q2 2023; adjusted loss per share was $0.17 versus $0.12 last year.

• Net loss for Q2 2024 was $8.0 million, or $0.17 per share, compared to $5.1 million, or $0.11 per share, in Q2 2023.

• Cash and investments totaled $114 million at quarter end; long-term debt was $61.9 million.

Outlook and guidance

• Full-year 2024 revenue guidance revised to $456–$461 million, reflecting ~15% growth over 2023.

• Adjusted EBITDA expected between $26–$29 million, a 34%–49% improvement over 2023.

• Adjusted loss per share forecasted at $0.74–$0.82 for 2024.

• Anticipate low single-digit sequential revenue decline in Q3 due to seasonality, with rebound in Q4.

• Guidance incorporates new product launches, international expansion, and continued investment in growth catalysts.